ferrets stock to watch karmelsonix limited

Ferret's Stock to Watch: KARMELSONIX LIMITED

MEDICAL DEVICE TO MEASURE BREATHING DURING OPERATIONS OVERVIEW


Ferret says talking about a Stock to Watch below 9c is a rarity.

Such a share price is often classified in the market as a real punting
stock.


But price for a small biotech equipment maker called KarmelSonix
(ASX:KSX) is not the real criteria to elicit support - although it
helps.


It is what the company is trying to achieve that should be the real
market driver.


Firstly the company has had its ups and down in management and now
appears much more stable and on track.


On Tuesday, the company produced an important announcement.


It said that its subsidiary Pulmosonix Pty Ltd has completed the first
of its specific milestones consistent with previous developments
released to the Australian Stock Exchange last year.


The pre-clinical evaluation of the AirwayClear as an upper airway
patency monitor has indicated that there is a gap in the market place
for a product that will provide anaestheticians, recovery rooms, ICUs
and emergency rooms with immediate information in respect to airway
patency caused by upper airway respiratory obstruction or constriction
as opposed to the delayed response provided by Pulse Oximetry.


The company has highlighted the following:


Pulmosonix Pty Ltd confirms completion of its first performance
milestone;


Preclinical evaluation of AirwayClear for monitoring airway patency
during airway obstruction or constriction has demonstrated that there
is a clinical need and a market need for this type of product in the
area of conscious sedation monitoring;


A clinical trial has been initiated to determine the efficacy of
AirwayClear as an airway patency monitor in acute asthma through the
Alfred Hospital in Melbourne;


PulmoScreen clinical trials have been completed at the Alfred Hospital.


The PulmoSonix-owned PulmoScreen technology trial at the Alfred
Hospital has shown early promising results and is currently undergoing
intensive analysis with further updates to be provided.


KSX chairman Peter Marks indicated that the completion of the
Pulmosonix milestones is another significant step in the further
development of the company.


Both the Melbourne- and Haifa (Israel)-based research and development
teams have continued to meet their development milestones consistent
with the plans developed by the company and enunciated last November
when PulmoSonix in Melbourne and Karmel Medical in Israel came together
under the KarmelSonix entity.


KSX is now moving to accelerate its development timetable of new
products based on its acoustic technology platform.


The completion of this work marks the completion of the PulmoSonix
first milestone and the release of 14.5 million F-class shares as
approved at the meeting of shareholders last November.


Achievement of the above signifies the completion of the requirements
in relation to the receipt by PulmoSonix of the first tranche shares to
be issued, including the release of 10 million F-class shares to Medic
Vision Ltd (formerly Premier Bionics Ltd) and 4.5 million F-class
shares to KSX directors and corporate advisors.


Reference is also made to the announcement dated April 11 confirming
the completion of the KarmelSonix Israel initial technical milestones
in relation to the WIM-PC technology for acute asthma monitoring and
the resultant release of 19.5 million C-class shares.


It is expected that the issue of all of the above shares to the various
parties will be completed this month.


SHARE PRICE MOVEMENTS


Shares of KarmelSonix yesterday eased 0.8c to 9.8c. Rolling high for
the year is 11.5c and low 2.2c. The company has 169.8 shares on issue
with a market cap of $16.6 million.


KarmelSonix has appointed Israel Tal as corporate VP of sales and
marketing.


Prior to joining the KarmelSonix team, Mr Tal served as director of
business development at SHL Telemedicine Ltd, a public healthcare
company specialising in home monitoring of cardiac patients and sales
of telemedicine systems and then as VP of sales in Power Paper Ltd, a
consumer skin-care technology company marketing innovative intra/trans
dermal micro-electrical patches.


Mr Tal has extensive marketing and sales background in cardiopulmonary
and consumer health products and services, experienced in managing
sales and marketing of new products and innovative concepts in the
medical arena.


He has wide commercial experience and proven track record in
international sales and execution of multiple multi-million dollar
distribution deals.


In recent years he spearheaded the introduction of several novel
devices and disease management concepts which involved upgrading
traditionally practiced standard of care towards more advanced
alternatives.


As part of his role Mr Tal will:


Establish the KSX internal and external sales & commercial
infrastructure and initiate independent marketing and sales activities
of the recently completed WIM-PC in selected regions through
KS-appointed regional distributors; and


Develop and enhance the KSX existing commercial relationships with
nSpire Inc, an international manufacturer and seller of pulmonary
function testing (PFT) devices and services with special focus on
asthma and the Spiro-WIM device/system.


Mr Tal joins the key management team of KarmelSonix, lead by Dr Reuven
Regev, CEO and executive director, chief medical officer Prof Noam
Gavriely and CTO Itzik Kroin to spearhead the company's commercial
operations. BACKGROUND


KarmelSonix Ltd, formerly Salus Technologies Ltd, is a medical devices
company focused on providing acoustic-based non-invasive clinical
solutions for the monitoring and management of cardio-pulmonary
conditions such as asthma, sleep apnea and emphysema.


KarmelSonix is the parent company of both KarmelSonix (Israel) Ltd
(KSI), based in Haifa, Israel, and PulmoSonix Pty Ltd (KSA),
headquartered in Melbourne.


KSA and KSI have the same board of directors with Peter Marks of
Melbourne serving as chairman, and Dr Reuven Regev of Haifa serving as
executive director and CEO of the entire group.


The Australian and the Israeli subsidiaries are both focused on
pulmonary acoustics as diagnostic and monitoring tools for managing
asthma and other pulmonary disorders.


Asthma management requires definite diagnosis, accurate staging and
long-term follow up.


With the company's technology, it is possible, for the first time to do
so without the need for extensive patient co-operation.


Automatic wheeze, cough and breath detection facilitate quantitative,
objective and non-invasive assessment of asthma activity for all ages
and around the clock.


The company's devices are being developed in the field of respiratory
medicine and include diagnosis, monitoring and control of these
respiratory conditions.